Doxinil 100
Broad spectrum antibiotic
  • Doxycycline hyclate is a synthetically derived tetracycline with bacteriostatic properties against broad spectrum of bacteria sensitive to tetracycline and has  some antiprotozoal properties, It acts by inhibiting protein synthesis in these organisms.
  • The special pharmacological profile of Doxycycline with high absorption in the GIT, high penetration of tissues, and long biological half-life (15 - 25 hours) make it possible to maintain blood and tissue concentration for  
    24 hours after a single dose. Doxycycline thus affords such clinical advantages as single daily dosage for most patients.
  • Doxycycline absorption is not affected by food and bound to plasma proteins by 80 - 95% , Doxycycline is not excreted in the urine to the same extent as are other  tetracyclines and it does not accumulate in blood of 
    patients with renal failure. It is thus the safest of the tetracyclines in the treatment of renal and extra renal infections.
  • Doxycycline is excreted in faeces up to 90% as an inactive conjugate or as a chelate, for this reason it has relatively less effect on intestinal micro flora.

Each capsule of Doxinil 100 contains:

  • Doxycycline 100 mg (as Doxycycline Hyclate)

DOXINIL® is indicated in the following infections caused by susceptible organisms:

  • Infections of respiratory tract: pneumonia, laryngitis, sinusitis, bronchitis, tonsillitis and otitis.
  • Infections of urinary tract caused by Klebsella and E.coli.
  • Infections of gastrointestinal tract and the bile duct.
  • Venereal infections as syphilis, gonorrhea, lymphogranuloma.
  • Pelvic inflammatory disease in women.
  • Other infections: infections of skin and soft tissues, oral and dental infections, severe acne, eye infections and malta fever.
  • As an adjunct in the treatment of malignant Plasmodium Falciparum malaria
  • Hypersensitivity to tetracyclines. 
  • Children below the age of 8 years, owing to the risk of discoloration of the permanent teeth.
  • Severe liver malfunction. 
  • Doxycycline absorption is less likely to be affected by milk or food, although it is still affected by antacids containing aluminium, calcium or magnesium and iron preparations, thus antacids should be taken 2 hours before or after DOXINIL® administration.
  • Oral Doxycycline reportedly may potentiate  the effects of oral anticoagulants.
  • DOXINIL® decrease insulin demand.
  • DOXINIL® decrease the efficacy of oral contraceptive.
  • DOXINIL® may increase the toxic effects of ergot alkaloids and methotrexate. 
  • Concomitant use of penicillins and DOXINIL® must be avoided. 
  • Alcohol, barbiturates, carbamazepine and phenytoin reduce the time of doxycycline’s half life in blood.
  • Concomitant use of DOXINIL® and methoxyflurane in anesthesia has reported to cause fatal renal dysfunction.  
  • Not recommended.


  • Gastrointestinal complaints such as nausea, loss of appetite, vomiting and diarrhea.
  • Photosensitivity.

¤ Capsule should be swallowed with a plenty of fluid in the sitting or standing position. 

  • 200 mg as a single dose in the first 24 hours followed by 100 mg/24 hours. 
  • In severe infections: 200 mg daily. 

Children: (8-12 years):

  • 4 mg/kg body weight during the first 24 hours, followed by 2 mg/kg body weight every 24 hours.
  • DOXINIL® Should only be used for children below  8years of age on very strong indications.

¤ Or as directed by the physician.

  • Drug should be discontinued at the first sign of erythema or super infection.
  • Renal, hepatic and haematologic systems should be evaluated periodically during prolonged therapy. 

DOXINIL® Capsule 100 mg;

  • (Blister of 10 capsules, Pack of one blister.)

¤ Hospital packs of different sizes.

  • Store in a dry place at a temperature below 25°C. 
  • Protect from light.